Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

This study tested a new tablet called TQ05105 against a standard drug (hydroxyurea) in 107 people with moderate or high-risk myelofibrosis, a rare bone marrow disorder. The main goal was to see if the new drug could shrink the spleen by at least 35% after 24 weeks. Participants w…

This study tested a new drug (TQB3616) combined with fulvestrant in 122 people with a type of advanced breast cancer (HR-positive, HER2-negative). The goal was to see if the combination could shrink tumors or slow the cancer's growth. Participants had either received one prior tr…

This study tested whether adding the experimental drug TQB3616 to standard hormone therapy (fulvestrant) can help slow cancer growth in people with a common type of advanced breast cancer (HR-positive, HER2-negative). About 293 women took part, receiving either the drug combo or …

This study tested an experimental drug called TQC2731 in 205 adults with severe asthma that is not well controlled by current treatments. Participants received either one of three doses of TQC2731 or a placebo as a shot every 4 weeks for about a year. The main goal was to see if …

This study tested an experimental pill called TQA3605 in 122 adults with chronic hepatitis B who still had low amounts of virus despite standard treatment. Participants took either TQA3605 plus their usual antiviral drug or a placebo plus their usual drug for 24 weeks. The main g…

This study tested a new drug combination (TQB2618 plus penpulimab) in 47 people with advanced nasopharyngeal carcinoma that had come back or spread. Some participants had already tried standard treatments, while others were new to therapy. The goal was to see if the combination w…

This early-phase study tested a new daily pill called TQB3616 in 40 adults with advanced breast cancer that had stopped responding to standard hormone therapy. The pill works by blocking a protein that helps cancer cells multiply. The main goals were to find a safe dose and under…

This early-phase trial tested an experimental drug called AL2846 in 33 people with a type of thyroid cancer that no longer responds to standard treatments. The goal was to see if the drug could shrink tumors or slow the cancer's growth. Participants took the drug by mouth, and do…

This early-phase study tested a new pill called TQ05105 in 79 adults with certain blood cancers (myeloproliferative neoplasms). The main goals were to find the safest dose and check for side effects. Participants had to be 18 or older and have a specific type of blood cancer. The…

This study looked at how certain drugs change the way TQ05105 tablets are processed in the body. It involved 40 healthy adults aged 18 to 45. The goal was to measure drug levels and safety when TQ05105 is taken with other medications. This helps doctors understand potential drug …

This study gave a single dose of a radioactive-labeled drug, TQ05105, to 6 healthy Chinese men. Researchers measured how much of the drug left the body in urine and stool, and how it changed in the blood. The goal was to understand how the drug is broken down and removed, not to …

This study looked at how the body processes an experimental antibiotic called TQD3606 in people with different levels of kidney function. 32 adults received a single dose, and researchers measured drug levels in blood and urine. The goal was to understand safety and drug clearanc…

This study checked whether a generic version of eltrombopag (a drug that helps increase blood platelets) works the same as the brand-name drug in healthy adults after eating. Thirty-six healthy Chinese volunteers took both versions at different times, and researchers measured how…

This study looked at how the body processes a new antibiotic called TQD3524 in people with different levels of kidney function. 48 adults with kidney problems received a single dose to measure drug levels and safety. The goal was to understand dosing, not to treat the infection d…